| The Wall Street Journal Western Edition 1998 Robert Langreth |
| Title | Subject | Authors |
|---|
| Breast-cancer drug is backed by FDA panel. | Business, general | Robert Langreth |
| Cephalon receives marketing approval for Provigil medication for narcolepsy.(Abstract) | Business, general | Robert Langreth, Laurie McGinley |
| Diabetes study supports drug therapy. | Business, general | Robert Langreth |
| Diet drug, heart valve link bolstered by studies. | Business, general | Robert Langreth, Laura Johannes |
| FDA approves a new drug for arthritis.(Enbrel from Immunex Corp. approved)(Abstract) | Business, general | Robert Langreth |
| Hoechst to intensify marketing battle with Immunex Corp. on arthritis drug.(Abstract) | Business, general | Robert Langreth |
| J&J faces diminished blockbuster-drug pipeline.(Johnson & Johnson loses the right to sell new anemia drug)(Abstract) | Business, general | Robert Langreth |
| J&J plans job cuts, $800 million charge.(Johnson and Johnson)(Abstract) | Business, general | Robert Langreth, Ron Winslow |
| Johnson & Johnson profit rose 11% in second quarter. | Business, general | Robert Langreth |
| Merck gets FDA approval for migraine drug. | Business, general | Robert Langreth |
| Merck reports positive test results for new type of antidepressant drug. | Business, general | Robert Langreth |
| Merk, Astra reach restructuring pact. | Business, general | Steven Lipin, Robert Langreth |
| Two painkillers add up to one marketing battle.(Searle's Celebrex vs. Merck's Vioxx will compete for arthritis sufferers)(Abstract) | Business, general | Robert Langreth, Thomas M. Burton |
| Viagra's lesson: new drugs, unknown risks. | Business, general | Robert Langreth, Nancy Ann Jeffrey |
| Warner-Lambert and Glaxo end a venture on ulcer drug Zantac. | Business, general | Robert Langreth |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
